Cargando…
Measurable residual disease in the treatment of chronic lymphocytic leukemia
Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in severa...
Autores principales: | Uchiyama, Takayoshi, Yokoyama, Aki, Aoki, Sadao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Lymphoreticular Tissue Research
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810249/ https://www.ncbi.nlm.nih.gov/pubmed/33148932 http://dx.doi.org/10.3960/jslrt.20014 |
Ejemplares similares
-
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic
anemia due to ibrutinib treatment
por: Suzuki, Takaharu, et al.
Publicado: (2018) -
Highlights: B-chronic lymphocytic leukemia: Current diagnostic characteristics of and treatments for chronic lymphocytic leukemia in Japan
por: Aoki, Sadao
Publicado: (2020) -
Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023) -
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
por: Wierda, William G., et al.
Publicado: (2021) -
Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)